Evaluating Microarray Pharmacogenetic Testing in Cancer Patients

Description

The purpose of this research is to evaluate the impact of a microarray PGx test on prescribing/dosing of drugs and cancer treatments in patients with cancer who are currently eligible for single-gene DPYD testing.

Conditions

Cancer, Gastrointestinal Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this research is to evaluate the impact of a microarray PGx test on prescribing/dosing of drugs and cancer treatments in patients with cancer who are currently eligible for single-gene DPYD testing.

Evaluating the Use of Microarray Pharmacogenetic Testing in Patients with Cancer

Evaluating Microarray Pharmacogenetic Testing in Cancer Patients

Condition
Cancer
Intervention / Treatment

-

Contacts and Locations

Charlotte

Atrium Health Levine Cancer, Charlotte, North Carolina, United States, 28204

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Written informed consent and HIPAA authorization for release of personal health information.
  • * Age ≥ 18 years at the time of consent.
  • * Eligible for standard of care single-gene DPYD testing (i.e., receiving or expected to receive a fluoropyrimidine-based chemotherapy regimen). The potential participant meets inclusion criteria if the standard of care single-gene DPYD test is planned or previously ordered. If previously ordered, consent must occur no later than 60 days from the date the DPYD results were available.
  • * Willing to provide additional buccal swabs if residual DNA from previous DPYD testing is inadequate for microarray testing.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Wake Forest University Health Sciences,

Jai Patel, PharmD, PRINCIPAL_INVESTIGATOR, Atrium Health Levine Cancer

Study Record Dates

2025-05